Advertisement
Singapore markets close in 5 hours 30 minutes
  • Straits Times Index

    3,301.76
    +8.83 (+0.27%)
     
  • Nikkei

    38,236.07
    -38.03 (-0.10%)
     
  • Hang Seng

    18,461.53
    -14.39 (-0.08%)
     
  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     
  • Bitcoin USD

    63,855.15
    +770.48 (+1.22%)
     
  • CMC Crypto 200

    1,326.43
    +49.45 (+3.87%)
     
  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     
  • Dow

    38,675.68
    +449.98 (+1.18%)
     
  • Nasdaq

    16,156.33
    +315.33 (+1.99%)
     
  • Gold

    2,317.50
    +8.90 (+0.39%)
     
  • Crude Oil

    78.30
    +0.19 (+0.24%)
     
  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     
  • FTSE Bursa Malaysia

    1,593.13
    +3.54 (+0.22%)
     
  • Jakarta Composite Index

    7,140.88
    +6.15 (+0.09%)
     
  • PSE Index

    6,678.39
    +62.84 (+0.95%)
     

HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024

PLYMOUTH MEETING, Pa., April 16, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30, 2024, before the open of the U.S. financial markets. Harmony will host a conference call and live webcast on April 30, 2024, at 8:30 a.m. ET to discuss the results.

Harmony Biosciences logo (PRNewsfoto/Harmony Biosciences)
Harmony Biosciences logo (PRNewsfoto/Harmony Biosciences)

To participate in the call, please dial (800) 579-2543 (domestic) or +1 (785) 424-1789 (international), and reference passcode HRMYQ124. It is recommended that you dial in at least 10 minutes prior to the call.

The live and replay webcast of the call will be available on the investor page of our website at https://ir.harmonybiosciences.com/.

ADVERTISEMENT

About Harmony Biosciences
At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases that others often overlook. We believe that where empathy and innovation meet, a better life can begin for people living with neurological diseases. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, PA, our team of experts from a wide variety of disciplines and experiences is driven by our shared conviction that innovative science translates into therapeutic possibilities for our patients, who are at the heart of everything we do. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Luis Sanay, CFA
445-235-8386
lsanay@harmonybiosciences.com

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-report-first-quarter-2024-financial-results-on-april-30-2024-302117222.html

SOURCE Harmony Biosciences